“…Study findings also contribute to the growing body of evidence that thoughtful genotyping processes can help overcome potential ethical questions with student personal genotype evaluation, including concerns about student vulnerability, exploitation, or coercion, the possibility of returning test results with unclear or shifting clinical implications for disease risk, and a blurred line between educational and human subject research. 14,15,28,29 We employed measures to protect students that included the use of an honest broker intermediary for all study-related communication, faculty blinding to student genotyping choice, coverage of bioethics and informed consent for genetic testing prior to genotyping offer, offer of genetic counseling at no charge, and use of specific verbiage during question-and-answer sessions to avoid revealing students' genotyping choice. Although there is minimal risk of incidental findings or disease associations with the pharmacogenetic SNP data, we also conducted searches of the database of Genotypes and Phenotypes (dbGaP), and the National Human Genome Research Institute Genome-Wide Association Study (NHGRI GWAS) Catalog on all SNPs prior to the start of the course and again before returning any student genotyping data to identify and remove any SNPs that could be associated with disease risk.…”